AstraZeneca Expands AI Partnership with Immunai Through 2027

2026-05-08 00:11:34

AstraZeneca has expanded its partnership with New York-based AI biotech company Immunai through 2027, according to Calcalist. Under the expanded agreement, Immunai is eligible to receive up to $37.5 million in 2026 and 2027 as the drugmaker continues integrating its platform into oncology drug development programs.

Technology Platform and Applications

Imunai's AMICA-OS platform analyzes clinical immunology data at the single-cell level. AstraZeneca said it will use the system for biomarker discovery, patient stratification, dose optimization, and mechanism-of-action analysis across its oncology programs. The companies expanded the collaboration into inflammatory bowel disease research in 2025, broadening the platform's application beyond cancer-focused work.

Partnership Evolution

The current agreement builds on a 2024 partnership to use Immunai's platform in oncology clinical programs. The companies' collaboration traces back to 2022, when an initial phase focused on improving oncology trials included an $18 million investment by AstraZeneca. As of September 2024, Immunai had raised approximately $270 million in total funding. The company reported that 85 of its 170 employees hold PhD or MD degrees, and stated it has secured more than 30 partnerships with Fortune 100 drug companies and leading academic institutions.

View Source

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

05-07 21:01

Nvidia Secures 30M Warrant Options from Bitcoin Miner IREN to Deploy 5GW AI Infrastructure

05-07 15:13

CZ Says YZi Labs Allocates 70% to Blockchain, 20% to AI at Consensus Miami 2026

05-07 13:04

Blitzy Completes $200M Funding Round Led by Northzone

Genesis AI Launches GENE-26.5 Robotics Platform With US$105M Funding

Crypto Frontier05-07 07:51

a16z launches its 5th fund with $2.2 billion in crypto, leading an investment in three AI startups

Market Whisper05-07 03:27

DeepSeek Raises Funding at $45B Valuation Amid AI Competition

Crypto Frontier05-07 01:22

Hut 8 Shares Jump 30% on $9.8B AI Data Center Lease

Crypto Frontier05-06 20:39

OpenAI Unveils the MRC Supercomputer Network Protocol! Teaming Up with NVIDIA, AMD, and Microsoft to Build the Stargate Infrastructure

ChainNewsAbmedia05-06 16:05

Comment

0/400

ProofOfNap

· 05-08 17:40

The AI narrative in biopharmaceuticals has finally moved from 'proof of concept' to the stage of 'annual renewal,' which demonstrates the platform's value more than any paper.

View OriginalReply0

GweiGossip

· 05-08 00:22

AZ and Immunai's collaboration has been extended to 2027. Thirty-seven and a half million dollars may not be an astronomical figure for AI-driven drug development, but the reduction in trial-and-error costs for the oncology pipeline can be much more than that.

View OriginalReply0

Frost-ColoredCubeCity

· 05-08 00:19

Curious about the structure of this funding, is it milestone-based or platform access fee? Spreading it over the two years of 2026-2027, the burn rate pressure on Immunai won't be small.

View OriginalReply0

GateUser-6319729f

· 05-08 00:16

Traditional large pharmaceutical companies are clearly accelerating their pace in AI-driven target discovery, and platforms like Immunai that have real-world data plus immune mapping are indeed rare.

View OriginalReply0